These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rituximab. Chronic lymphoid leukaemia: no decisive advantage.
    Journal: Prescrire Int; 2010 Apr; 19(106):56-8. PubMed ID: 20568482.
    Abstract:
    When treatment is needed for patients with symptomatic chronic lymphoid leukaemia, the standard first-line treatment is oral chlorambucil. Fludarabine has been used more as a second-line option. Rituximab has been authorised for use in both first-line and second-line therapy. We found no randomised trials comparing rituximab versus either chlorambucil or fludarabine. Clinical evaluation of rituximab is mainly based on 2 randomised unblinded trials, comparing cytotoxic chemotherapy, with and without the addition of rituximab, as first-line treatment in 817 patients in one trial and as second-line treatment in 552 patients in the other trial. Most patients were at a relatively early stage of the disease. After a median follow-up of about 2 years, addition of rituximab increased median progression-free survival by about 7 to 10 months. It was also associated with a higher complete response rate (about 10% to 20% higher). Follow-up was too short to reliably estimate the possible impact on overall survival. In the trial of first-line treatment, adverse events were more frequent in the rituximab group (77% versus 62%), especially serious infections (18% versus 15%) and febrile neutropenia (8% versus 6%). In the trial of second-line therapy, there were more fatal adverse events in the rituximab group (13% versus 10%). Rituximab also carries a risk of progressive multifocal leukoencephalopathy. In practice, adding rituximab to other cytotoxic drugs has no proven benefit in previously untreated patients with chronic lymphoid leukaemia. In second-line treatment, the progression-free survival benefit associated with rituximab must be weighed against the increase in adverse effects.
    [Abstract] [Full Text] [Related] [New Search]